Total Payments
$6.2M
2024 Payments
$541,455
Companies
70
Transactions
6,210
Medicare Patients
855
Medicare Billing
$780,187
Payment Breakdown by Category
Other$3.3M (53.8%)
Consulting$2.2M (35.5%)
Travel$549,912 (8.9%)
Food & Beverage$95,331 (1.5%)
Research$15,529 (0.3%)
Education$419.67 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.2M | 1,107 | 51.2% |
| Consulting Fee | $2.2M | 712 | 35.5% |
| Travel and Lodging | $549,912 | 1,342 | 8.9% |
| Honoraria | $160,974 | 54 | 2.6% |
| Food and Beverage | $95,331 | 2,975 | 1.5% |
| Unspecified | $15,529 | 9 | 0.3% |
| Education | $419.67 | 9 | 0.0% |
| Grant | $85.45 | 2 | 0.0% |
Payments by Type
General
$6.2M
6,201 transactions
Research
$15,529
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $3.0M | 1,706 | $0 (2022) |
| ABBVIE INC. | $1.2M | 1,203 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $581,887 | 619 | $0 (2024) |
| Lilly USA, LLC | $508,755 | 672 | $0 (2024) |
| Amgen Inc. | $269,102 | 369 | $0 (2023) |
| Lundbeck LLC | $130,966 | 233 | $0 (2024) |
| H. Lundbeck A S | $125,167 | 42 | $0 (2024) |
| Biohaven Pharmaceutical Holding Company Ltd. | $83,809 | 143 | $0 (2022) |
| Supernus Pharmaceuticals, Inc. | $60,579 | 218 | $0 (2022) |
| Biohaven Pharmaceuticals, Inc. | $59,500 | 119 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $541,455 | 557 | ABBVIE INC. ($377,674) |
| 2023 | $477,082 | 663 | AbbVie Inc. ($306,704) |
| 2022 | $654,619 | 737 | ABBVIE INC. ($294,977) |
| 2021 | $855,486 | 892 | Allergan, Inc. ($388,827) |
| 2020 | $902,600 | 733 | Allergan, Inc. ($565,119) |
| 2019 | $892,735 | 1,011 | Allergan Inc. ($506,722) |
| 2018 | $1.1M | 888 | Allergan Inc. ($802,691) |
| 2017 | $750,606 | 729 | Allergan Inc. ($628,258) |
All Payment Transactions
6,210 individual payment records from CMS Open Payments — Page 1 of 249
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | ABBVIE INC. | QULIPTA (Drug) | Travel and Lodging | In-kind items and services | $100.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/27/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $47.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/27/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $5.46 | General |
| Category: NEUROSCIENCE | ||||||
| 12/27/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $5.09 | General |
| Category: NEUROSCIENCE | ||||||
| 12/23/2024 | ABBVIE INC. | QULIPTA (Drug) | Consulting Fee | Cash or cash equivalent | $9,200.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 12/23/2024 | ABBVIE INC. | QULIPTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/20/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: PAIN | ||||||
| 12/19/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: PAIN | ||||||
| 12/18/2024 | ABBVIE INC. | UBRELVY (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 12/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 12/18/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $39.95 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/16/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $1,320.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | Lundbeck LLC | VYEPTI (Biological) | Travel and Lodging | Cash or cash equivalent | $294.61 | General |
| Category: NEUROLOGY | ||||||
| 12/16/2024 | Lundbeck LLC | VYEPTI (Biological) | Travel and Lodging | Cash or cash equivalent | $234.98 | General |
| Category: NEUROLOGY | ||||||
| 12/16/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $11.67 | General |
| Category: NEUROLOGY | ||||||
| 12/15/2024 | Lundbeck LLC | VYEPTI (Biological) | Travel and Lodging | Cash or cash equivalent | $204.10 | General |
| Category: NEUROLOGY | ||||||
| 12/13/2024 | H. Lundbeck A S | VYEPTI (Biological) | Honoraria | Cash or cash equivalent | $1,750.00 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | Lundbeck LLC | VYEPTI (Biological) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: NEUROLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/11/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: PAIN | ||||||
| 12/10/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | ABBVIE INC. | $7,110 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $3,750 | 1 |
| RIMEGEPANT SULFATE ZAVEGEPANT MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $1,446 | 4 |
| Post-hoc analysis to assess for wearing-off of erenumab using the pivotal trial data and pharmacoki | Amgen Inc. | $22.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 155 | 30,242 | $526,428 | $175,196 |
| 2022 | 4 | 128 | 9,607 | $175,758 | $59,718 |
| 2021 | 7 | 256 | 42,018 | $569,706 | $240,368 |
| 2020 | 7 | 316 | 56,248 | $732,872 | $304,904 |
Total Patients
855
Total Services
138,115
Medicare Billing
$780,187
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 50 | 30,000 | $432,800 | $148,877 | 34.4% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 49 | 146 | $66,430 | $17,470 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 20 | 37 | $11,544 | $3,910 | 33.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 45 | $9,270 | $3,092 | 33.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $6,384 | $1,847 | 28.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 37 | 9,500 | $130,600 | $46,351 | 35.5% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 35 | 46 | $20,510 | $5,608 | 27.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 39 | 39 | $17,784 | $5,417 | 30.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 22 | $6,864 | $2,342 | 34.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 81 | 41,576 | $464,641 | $201,668 | 43.4% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 78 | 202 | $71,175 | $23,093 | 32.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time per calendar month | Office | 2021 | 22 | 145 | $11,320 | $4,829 | 42.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 24 | 29 | $7,275 | $4,301 | 59.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 20 | 29 | $6,472 | $2,872 | 44.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $4,893 | $2,006 | 41.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 19 | 25 | $3,930 | $1,601 | 40.7% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 116 | 55,865 | $619,155 | $266,022 | 43.0% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2020 | 111 | 265 | $92,750 | $30,457 | 32.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 39 | 56 | $8,120 | $3,087 | 38.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 12 | 12 | $4,956 | $1,941 | 39.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 11 | 13 | $3,575 | $1,565 | 43.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 12 | 12 | $2,364 | $939.30 | 39.7% |
| 99490 | Chronic care management services at least 20 minutes per calendar month | Office | 2020 | 15 | 25 | $1,952 | $892.25 | 45.7% |
About Dr. Andrew Blumenfeld, M.D
Dr. Andrew Blumenfeld, M.D is a Neurology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164459913.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Blumenfeld, M.D has received a total of $6.2M in payments from pharmaceutical and medical device companies, with $541,455 received in 2024. These payments were reported across 6,210 transactions from 70 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($3.2M).
As a Medicare-enrolled provider, Blumenfeld has provided services to 855 Medicare beneficiaries, totaling 138,115 services with total Medicare billing of $780,187. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Los Angeles, CA
- Active Since 06/27/2006
- Last Updated 02/03/2026
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1164459913
Products in Payments
- BOTOX (Biological) $1.7M
- UBRELVY (Drug) $644,851
- BOTOX (Drug) $340,402
- AJOVY (Biological) $319,673
- BOTOX THERAPEUTIC (Biological) $269,866
- EMGALITY (Drug) $247,808
- AJOVY (Drug) $236,849
- VYEPTI (Biological) $217,084
- Aimovig (Biological) $213,422
- QULIPTA (Drug) $188,730
- NURTEC ODT (Drug) $175,706
- REYVOW (Drug) $78,910
- TROKENDI XR (Drug) $60,486
- BOTOX - MIGRAINE (Drug) $55,766
- Zembrace (Drug) $39,457
- BOTOX CHRONIC MIGRAINE (Drug) $37,473
- ONZETRA Xsail (Drug) $33,952
- TREXIMET (Drug) $27,915
- BOTOX COSMETIC (Biological) $21,542
- Cambia (Drug) $18,626
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Los Angeles
Jeffrey Cummings, Md, MD
Neurology — Payments: $1.2M
Neurology $1.2M
Dr. Alan Rapoport, M.d, M.D
Neurology — Payments: $1.0M
Neurology $1.0M
Said Beydoun, M.d, M.D
Neurology — Payments: $967,384
Neurology $967,384
Mark Lew, M.d, M.D
Neurology — Payments: $735,848
Neurology $735,848
Dr. Dawn Eliashiv, M.d, M.D
Neurology — Payments: $465,988
Neurology $465,988
Margaret Burnett, M.d, M.D
Neurology — Payments: $413,050
Neurology $413,050